Table 2 .
Baseline (visit 1) and follow-up results (mean ± SD) at 3 months (visit 2) and 6 months (visit 3) on intervention and after 6 months off intervention (visit 4) for the subjects with motor complete paraplegia who had at least one follow-up visit
| Characteristics | Baseline | Visit 2 | Baseline* | Visit 3 | Baseline* | Visit 4 |
|---|---|---|---|---|---|---|
| No. of Subjects | 9 | 9 | 8 | 8 | 8 | 8 |
| Total hip aBMD (g/cm2) | 0.71 ± 0.22 | 0.71 ± 0.22 | 0.68 ± 0.22 | 0.69 ± 0.21 | 0.68 ± 0.22 | 0.70 ± δ0.20 |
| Femur neck aBMD (g/cm2) | 0.75 ± 0.20 | 0.74 ± 0.19 | 0.73 ± 0.20 | 0.74 ± 0.18 | 0.73 ± 0.20 | 0.75 ± 0.16 |
| Tibia total vBMD (mg/cm3) | 167.69 ± 64.73 | 163.02 ± 61.45 | 168.39 ± 69.16 | 163.25 ± 64.18 | 168.39 ± 69.16 | 159.98 ± 59.32 |
| Tibia trabecular vBMD (mg/cm3) | 67.53 ± 54.58 | 66.17 ± 51.83 | 69.13 ± 58.12 | 64.66 ± 52.68 | 69.13 ± 58.12 | 63.99 ± 49.95 |
| Tibia cortical vBMD (mg/cm3) | 809.84 ± 52.87 | 788.81 ± 73.43 | 811.18 ± 56.36 | 804.23 ± 66.80 | 811.18 ± 56.36 | 793.51 ± 62.48 |
| Tibia trabecular number (1/mm) | 1.09 ± 0.51 | 1.10 ± 0.53 | 1.10 ± 0.54 | 1.04 ± 0.48 | 1.10 ± 0.54 | 1.02 ± 0.51 |
| Tibia trabecular separation (mm) | 1.15 ± 0.82 | 1.25 ± 1.12 | 1.18 ± 0.87 | 1.27 ± 1.05 | 1.18 ± 0.87 | 1.36 ± 1.15 |
| Tibia: trabecular thickness (mm) | 0.04 ± 0.03 | 0.04 ± 0.03 | 0.04 ± 0.03 | 0.04 ± 0.03 | 0.04 ± 0.03 | 0.04 ± 0.04 |
| Tibia cortical thickness (mm) | 0.80 ± 0.28 | 0.78 ± 0.29 | 0.79 ± 0.30 | 0.78 ± 0.31 | 0.79 ± 0.30 | 0.76 ± 0.31 |
| Tibia cortical area (mm2) | 86.47 ± 30.49 | 83.63 ± 31.40 | 83.44 ± 31.11 | 81.98 ± 31.76 | 83.44 ± 31.11 | 80.53 ± 32.17 |
| C-terminal peptide (CTX) (ng/ml) | 0.27 ± 0.16 | 0.34 ± 0.19 | 0.25 ± 0.15 | 0.26 ± 0.12 | 0.25 ± 0.15 | 0.23 ± 0.17 |
| Procollagen type 1 (P1NP) (µg/l) | 56.90 ± 25.55 | 54.57 ± 26.00 | 52.86 ± 24.05 | 48.38 ± 20.53 | 52.86 ± 24.05 | 54.95 ± 23.00 |
| Sclerostin (pmol/l) | 28.27 ± 12.52** | 30.69 ± 15.81** | 27.04 ± 13.24** | 29.43 ± 10.88** | 27.04 ± 13.24** | 31.98 ± 16.98** |
| Total body fat mass (kg) | 27.0 ± 12.4 | 26.9 ± 12.4 | 27.7 ± 13.1 | 28.0 ± 12.0 | 25.2 ± 11.9*** | 25.4 ± 10.5*** |
| Lower extremity fat mass (kg) | 9.1 ± 4.3 | 9.0 ± 3.9 | 9.4 ± 4.5 | 9.5 ± 4.0 | 8.0 ± 2.2*** | 8.1 ± 1.9*** |
| Total body lean mass (kg) | 39.6 ± 10.9 | 39.7 ± 10.5 | 38.3 ± 11.0 | 38.8 ± 11.3 | 39.5 ± 11.3*** | 39.8 ± 11.8*** |
| Lower extremity lean mass (kg) | 10.1 ± 3.4 | 10.2 ± 3.3 | 9.6 ± 3.3 | 9.7 ± 3.5 | 9.7 ± 3.5*** | 10.2 ± 4.0*** |
None of the differences were statistically significant.
*Baseline results for the eight corresponding subjects available at follow-visits.
**Sclerostin measurements were available for seven subjects at baseline, so baseline vs. visit 2 values correspond to seven subjects, while baseline vs. visits 3 and 4 values correspond to six subjects.
***Body composition variables were available for seven subjects instead of eight at visit 4, so baseline values are for the corresponding seven subjects.